Patient | Type* | Access | Agent | Result | Complications |
---|---|---|---|---|---|
1 | 1a-L | IPS | Onyx-34 | Cure | – |
2 | 2a | SOV | Onyx-34 | Cure | – |
3 | 3a | IPS | Onyx-34 | Cure | – |
4 | 1a | IPS | Onyx-34 | Cure | – |
5 | 3a | TO | Onyx-34 +PVA | Cure | Yes |
6 | 3a | TO | Onyx-34 | Cure | – |
7 | 3b | TO | Onyx-34 | Cure | – |
8 | 3a-L | TO | Onyx-34 | Cure | – |
9 | 3a-L | TO | Onyx-34 | Cure | – |
10 | 3c-L | TO | Onyx-34+coils | Cure | – |
11 | 3a-L | TO | Onyx-34 | Cure | – |
12 | 2b | TO | Onyx-34 | Cure | – |
13 | 2b | TO | Onyx-34 | Cure | – |
14 | 1b-L | IPS | Onyx-34 | Cure | – |
15 | 1b-L | TA | Onyx-18 | Cure | Yes |
16 | 3a-L | TO | Onyx-34 | Cure | – |
17 | 3a | TO | Onyx-34 | Cure | – |
18 | 3a | TO+TA | Onyx-34 | Cure | – |
19 | 3a-L | TA | Onyx-18 | Cure | Yes |
20 | 3a | TO | Onyx-34 | Cure | – |
21 | 2b | TO | Onyx-34 | Cure | – |
22 | 2b-L | TO+TA | Onyx-34/18 | Cure | – |
23 | 3a | TO | Onyx-34 | Cure | – |
24 | 3a-L | TA | Onyx-18 | Cure | Yes |
25 | 1c | IPS | PHIL-35 | Cure | Yes |
26 | 2b-L | IPS | PHIL-35 | Cure | – |
27 | 3a | TO | Onyx-34 | Cure | – |
28 | 3a | TO | PHIL-35 | Cure | – |
29 | 3a | TO | PHIL-35 | Cure | – |
30 | 3c-L | TO | PHIL-35 | Cure | – |
31 | 1a | IPS | Onyx-34 | Cure | – |
32 | 3c | TO | PHIL-35 | Cure | – |
*Type is based on our institutional classification described in an accompanying paper.
IPS, inferior petrosal sinus; PVA, polyvinyl alcohol; SOV, superior ophthalmic vein; TA, transarterial; TO, transorbital.